155 related articles for article (PubMed ID: 38901138)
1. New Insights of Target Therapy: Effects of Tyrosine Kinase Inhibitors on Male Gonadal Function: A Systematic Review.
Marino M; Cannarella R; Condorelli RA; Crafa A; La Vignera S; Calogero AE
Clin Genitourin Cancer; 2024 May; 22(5):102131. PubMed ID: 38901138
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
3. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.
Rambhatla A; Strug MR; De Paredes JG; Cordoba Munoz MI; Thakur M
J Assist Reprod Genet; 2021 Aug; 38(8):1897-1908. PubMed ID: 33826052
[TBL] [Abstract][Full Text] [Related]
4. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review.
Boskabadi SJ; Dashti A; Karevan S; Kargar-Soleimanabad S; Salehifar E
J Oncol Pharm Pract; 2023 May; ():10781552231174790. PubMed ID: 37170573
[No Abstract] [Full Text] [Related]
5. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
6. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors.
De Leo S; Trevisan M; Moneta C; Colombo C
Ann Endocrinol (Paris); 2023 May; 84(3):374-381. PubMed ID: 36963756
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
9. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
10. Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
Deb S; Boknäs N; Sjöström C; Tharmakulanathan A; Lotfi K; Ramström S
Cancer Med; 2020 Jan; 9(1):313-323. PubMed ID: 31714021
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Rinninella E; Cintoni M; Raoul P; Ponziani FR; Pompili M; Pozzo C; Strippoli A; Bria E; Tortora G; Gasbarrini A; Mele MC
Intern Emerg Med; 2021 Aug; 16(5):1341-1356. PubMed ID: 33337518
[TBL] [Abstract][Full Text] [Related]
12. The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Heine A; Schilling J; Grünwald B; Krüger A; Gevensleben H; Held SA; Garbi N; Kurts C; Brossart P; Knolle P; Diehl L; Höchst B
Cancer Immunol Immunother; 2016 Mar; 65(3):273-82. PubMed ID: 26786874
[TBL] [Abstract][Full Text] [Related]
13. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
14. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
15. Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.
Kronick O; Chen X; Mehra N; Varmeziar A; Fisher R; Kartchner D; Kota V; Mitchell CS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686630
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha SH; Kim K; Song YK
Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
[TBL] [Abstract][Full Text] [Related]
17. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
Wang Y; Travers RJ; Farrell A; Lu Q; Bays JL; Stepanian A; Chen C; Jaffe IZ
PLoS One; 2023; 18(11):e0294438. PubMed ID: 37983208
[TBL] [Abstract][Full Text] [Related]
18. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
Henriksen JN; Andersen CU; Fristrup N
Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
[TBL] [Abstract][Full Text] [Related]
20. Thyroid dysfunctions induced by tyrosine kinase inhibitors.
Fallahi P; Ferrari SM; Vita R; Di Domenicantonio A; Corrado A; Benvenga S; Antonelli A
Expert Opin Drug Saf; 2014 Jun; 13(6):723-33. PubMed ID: 24821006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]